Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma
European Institute of Oncology
European Institute of Oncology
University of Chile
Pliant Therapeutics, Inc.
The University of Queensland
NGM Biopharmaceuticals, Inc
R-Pharm
European Institute of Oncology
R-Pharm
Russian Academy of Medical Sciences
AO GENERIUM
Odense University Hospital
University of Kansas Medical Center
Azienda Ospedaliera di Perugia
RemeGen Co., Ltd.
Herlev Hospital
Centre Hospitalier Universitaire de Nice
TopAlliance Biosciences
JS InnoPharm, LLC
University Hospital Rijeka
University of California, Davis
Institute of Oncology Ljubljana
Assistance Publique - Hôpitaux de Paris
Peter MacCallum Cancer Centre, Australia
Leiden University Medical Center
Provectus Pharmaceuticals
University Hospital, Basel, Switzerland
The Netherlands Cancer Institute
OncoResponse, Inc.
Universitair Ziekenhuis Brussel
Massachusetts General Hospital
University of Utah
Karolinska University Hospital
Keio University
Massachusetts General Hospital
Centre Hospitalier Universitaire Vaudois
Biocad
Melanoma Institute Australia
Cedars-Sinai Medical Center
The Christie NHS Foundation Trust
Region Stockholm
Biocad
Kineta Inc.
BGI, China
Fujian Cancer Hospital
NovalGen Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
PrimeVax Immuno-Oncology Inc.
The Netherlands Cancer Institute
Namida Lab
Fudan University